Pirfenidone
ESBRIET
Pyridone
NADAC/unit
$1.5161
No Shortage
Tier 1: 66.0%
PA Req: 351.1%
14 Manufacturers
34 ANDAs
indicated for the treatment of idiopathic pulmonary fibrosis (IPF).
vs. brand ESBRIET: Generic saves up to 85% per unit
Market Intelligence
2023-03-08 Class II Recall: Accord Healthcare, Inc.
2023-03-08 Class II Recall: Accord Healthcare, Inc.
Generic Manufacturers
ACCORD HEALTHCARE INCAIZANT DRUG RESEARCH SOLUTIONS PRIVATE LTDALEMBIC PHARMACEUTICALS LTDAMNEAL EU LTDAPOTEX INCAUROBINDO PHARMA LTDHETERO LABS LTD UNIT VLAURUS LABS LTDLEGACY PHARMA INCMACLEODS PHARMACEUTICALS LTDMICRO LABS LTDMSN LABORATORIES PRIVATE LTDSANDOZ INCSCIEGEN PHARMACEUTICALS INCTEVA PHARMACEUTICALS USA INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.